Esophageal cancer can be diagnosed accurately by genetically analyzing lesions in the food pipe, says a new study led by researchers from Queen Mary University of London (QMUL), Academic Medical Center in Amsterdam and Arizona State University.
The study, published in Nature Communications
, shows that some cells that are 'born to be bad' could be identified early on, preventing the need for repeated endoscopies.
‘Some Barrett's esophagus lesions are 'born to be bad' or 'born to be benign. Genetic analysis of the lesion is a good predictor of which patients are at high risk of developing cancer.
Barrett's esophagus is a common condition that affects an estimated 1.5 million people in the UK alone, although many are undiagnosed. This condition involves normal cells in the esophagus (food pipe) being replaced by an unusual cell type called Barrett's esophagus, and is thought to be a consequence of chronic reflux (heartburn).
People with Barrett's have an increased risk of developing esophageal cancer - a cancer that has a five year survival of 15 percent. Although the overall lifetime risk of developing esophageal cancer in people with Barrett's is significant, most Barrett's patients will not develop cancer in their lifetime. It is the unfortunate few who will develop an aggressive cancer.
Currently there is no easy way to distinguish between high and low-risk Barrett's patients. Regular surveillance by endoscopy is the current best way to prevent cancer. During an endoscopy a camera is pushed into the esophagus to look for early signs of cancer, and treatment is then given to those who need it. A test based on the genetic make-up of the Barrett's lesions could benefit patients through improved diagnosis, giving people at high risk of cancer the best care, and reducing the burden of endoscopy for those at low risk.
Dr Trevor Graham from QMUL's Barts Cancer Institute said, "We have shown that some Barrett's esophagus lesions are 'born to be bad' - and conversely that some are 'born to be benign'. Once these results are validated in other patients and over longer periods of time, we will be able to say with confidence which people with the benign form can be spared unnecessary endoscopy and worry. This will dramatically improve the quality of life for people with Barrett's, and provide substantial cost saving to healthcare providers."
The team followed up more than 300 Barrett's patients over three years, and analyzed around 50,000 cells in the process. They performed genetic analysis of individual cells and measured the genetic diversity in each lesion to track it over time. The results validated a previous group's discovery that measurement of the genetic diversity between Barrett's cells in any given lesion is a good predictor of which patients are at high risk of developing cancer.
Genetic diversity describes how diverse the genetic make-up of individual cells is in any given group of cells. The reason that this is a good predictor of cancer risk could be because the more diverse the Barrett's cell population is, the more likely it is that one will be a 'bad egg' that will progress to cancer.
In addition, the team found that there were no significant changes in genetic diversity during the three years that the patients were followed. This suggests that the genetic diversity amongst a person's Barrett's cells is essentially fixed over time, and mutations have little impact on the lesion's development. Whenever someone's Barrett's is tested, their future risk can be predicted regardless of how soon it is after the appearance of abnormal cells.
Dr Graham commented, "Our findings are important because they imply that a person's risk of developing oesophageal cancer is fixed over time. In other words, we can predict from the outset which Barrett's patients fall into a high risk group of developing cancer - and that risk does not change thereafter."
Professor Sheila Krishnadath from the Academic Medical Center in Amsterdam said, "We have been working for over 10 years on collecting and typing single cells of this large group of Barrett's patients. The analysis by our unique collaboration indicates that the cancer risk in these relatively benign early lesions is determined by the number of abnormal clones that has been established in the Barrett's mucosa, rather than by specific gene abnormalities."